SWOG clinical trial number
SWOG-8221 (INT-0007)

Treatment of Advanced Bladder Cancer with Preoperative Irradiation and Radical Cystectomy versus Radical Cystectomy Alone

Closed
Phase
Accrual
81%
Published
Abbreviated Title
Treatment of Advanced Bladder Cancer with Preoperative Irradiation and Radical Cystectomy versus Radical Cystectomy Alone
Activated
10/29/1982
Closed
11/15/1989

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

1997

Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: A phase III intergroup study.

JA Smith Jr;ED Crawford;JC Paradelo;B Blumenstein;BR Herschman;HB Grossman;DW Christie Journal of Urology 157:806-808

1993

Pre-operative irradiation plus radical cystectomy versus surgery alone for invasive bladder cancer: Final results of a randomized, prospective Southwest Oncology Group study.

JA Smith Jr;ED Crawford;BL Blumenstein;J Paradelo;BR Herschman American Urological Association Inc. 149:316A(#415)

1987

Preoperative radiation therapy in the treatment of bladdercancer.

ED Crawford;S Das;JA Smith, Jr Urol Clinics of North Am 14(4):781-787

1984

Southwest Oncology Group experience with randomized protocols for bladder cancer.

JA Smith Jr;ED Crawford In: Controlled Clinical Trials in Urologic Oncology . L Denis, GP Murphy, GR Prout Jr, F Schroder, eds. New York: Raven Press 249-254

Other Clinical Trials

SWOG Clinical Trial Number
S2419

Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
Research Committee(s)
Genitourinary Cancer
Activated
04/22/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase